19 unknown. 19 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Unknown 19 |
| Phase 2 | 12 | Unknown 12 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMILES: Study of Montelukast in Sickle Cell Disease Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing | Phase 2 / Phase 3 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 200 | 2023-10-16 | 2023-11-01 |
| Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) HBOT in Hyperbaric chamber, Hyperbaric chamber for placebo - Sickle Cell Disease, Hyperbaric Oxygen Therapy | Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-09-15 | 2022-11-02 |
| Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus Mycophenolate Mofetil 500mg, Rituximab - Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus | Phase 3 | Unknown | Assiut University | 30 | 2021-09-15 | 2021-10-27 |
| Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients Acacia Senegal extract, Pectin - Sickle Cell Anemia in Children | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 100 | 2020-02-15 | 2020-01-28 |
| Comparison of Allogeneic Matched Related Haematopoietic Stem Cell Transplantation After a Reduced Intensity Conditioning Regimen With Standard of Care in Adolescents and Adults With Severe Sickle Cell Disease Allogeneic matched related haematopoietic stem cell transplantation, Standard arm - Sickle Cell Disease | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 78 | 2019-10-15 | 2019-09-23 |
| A Sickle CEll Disease ComplicatioN Trial SC411, Placebo - Sickle Cell Disease | Phase 3 | Unknown | Micelle BioPharma Inc | 210 | 2019-03-01 | 2019-02-01 |
| the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Sugammadex - Anesthesia, Pediatric Cancer | Phase 2 / Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 62 | 2018-11-15 | 2018-11-02 |
| Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial Influenza vaccine - Preventing Stroke in Sickle Cell Anaemia | Phase 2 / Phase 3 | Unknown | Makerere University | 150 | 2018-08-22 | 2018-09-12 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major | Phase 3 | Unknown | Ain Shams University | 24 | 2018-06-11 | 2023-03-06 |
| Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease Ketamine - Sickle Cell Disease | Phase 3 | Unknown | Augusta University | 20 | 2016-07-01 | 2016-06-15 |
| Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation non- fava beans - Glucose-6-Phosphate Dehydrogenase Deficiency | Phase 2 / Phase 3 | Unknown | Ain Shams University | 100 | 2015-12-01 | 2015-07-15 |
| Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements Omega-3 capsules, Placebo - Sickle Cell Disease | Phase 3 | Unknown | Sultan Qaboos University | 280 | 2015-09-01 | 2015-08-17 |
| An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Deferiprone - Beta Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2014-07-01 | 2015-01-14 |
| Role of Vitamin C to Augment Iron Chelation With DFP or DFX Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2014-04-01 | 2014-03-11 |
| Vascular Function Intervention Trial in Sickle Cell Disease Vascular ready-to-use supplementary food, Regular Ready-to-use supplementary food, Chloroquine - Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 120 | 2012-08-01 | 2016-07-27 |
| Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin. Hydroxyurea ,Epiao, hydroxyurea, blood transfusion - Thalassemia Intermedia | Phase 2 / Phase 3 | Unknown | Ain Shams University | 40 | 2012-06-01 | 2012-06-20 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2012-02-01 | 2012-02-06 |
| Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients Zoledronic acid, Placebo - Beta-Thalassemia, Bone Marrow Transplantation | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 50 | 2009-11-01 | 2011-07-26 |
| Therapeutic Effects of Silymarin in Patients With B-thalassemia Major Silymarin (LEGALON), Placebo - Beta-thalassemia Major, Iron Overload | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 140 | 2009-03-01 | 2009-10-21 |
Anemia, Sickle Cell (10) · beta-Thalassemia (9) · Anemia, Hemolytic, Autoimmune (1) · Glucosephosphate Dehydrogenase Deficiency (1) · Hemoglobin SC Disease (1) · Hepatitis C (1) · Hepatoblastoma (1) · Iron Overload (1) · Lupus Erythematosus, Systemic (1) · Neoplasms (1) · Sleep Apnea Syndromes (1) · Stroke (1) · Thalassemia (1) · Vaso-Occlusive Crises (1)
Anemia (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Anemia, Hemolytic, Congenital (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (18) · Hemoglobinopathies (17) · Thalassemia (8) · Metabolic Diseases (2) · Nervous System Diseases (2) · Nutritional and Metabolic Diseases (2) · Apnea (1) · Autoimmune Diseases (1) · Blood-Borne Infections (1)
Deferiprone (3) · Docosahexaenoic Acids (2) · Isoflurophate (2) · Ascorbic Acid (1) · Blood Transfusion (1) · Chloroquine (1) · Deferasirox (1) · Deferoxamine (1) · Fatty Acids, Omega-3 (1) · Gum Arabic (1) · Hydroxyurea (1) · Hyperbaric Oxygenation (1) · Influenza Vaccines (1) · Ketamine (1) · Mycophenolic Acid (1)
Ain Shams University (6) · Al-Neelain University (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Augusta University (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Isfahan University of Medical Sciences (1) · London School of Hygiene and Tropical Medicine (1) · Makerere University (1) · Micelle BioPharma Inc (1) · Sultan Qaboos University (1) · Tehran University of Medical Sciences (1) · University Hospital, Geneva (1)
Egypt (7) · Iran (2) · France (1) · Oman (1) · Russia (1) · Sudan (1) · Switzerland (1) · Tanzania (1) · Uganda (1) · United Kingdom (1)
Anna Konstantinova, MD (1) · Behjat Moayedi, Professor (1) · Beng Fuh, MD (1) · Carton Dampier, MD (1) · Fenella Kirkham, MA MB Bchir (1) · George Hsu, MD (1) · Imad M Fdl-Elmula, PhD (1) · Manal H El-Sayed, M.D (1) · Matt Heeney, MD (1) · Mohsen S Elalfy, professor (1) · Mohsen S Elalfy, professour (1) · Mohsen S. Elalfy, professour (1) · Sharon Cox, PhD (1)
PMID 23927461, PMID 25600572, PMID 29119631, PMID 29548623, PMID 34186262, PMID 34629091, PMID 37975597
2019 (1)